Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

Virtual Incision Robotically Assisted Surgical Device Use in Minimally Invasive Colectomy

NCT04703829 · tracked via the Priya Life Science USA tracker
Sponsor
Virtual Incision Corporation
Phase
Not applicable
Started
2021-08-09
Last updated
2026-10-27

Condition(s) studied

Colon CancerColon PolypDiverticular DiseasesInflammatory Bowel Diseases

Investigational drug(s) / intervention(s)

VI-RASD use in minimally invasive right or left colectomyRight or Left colectomy

VI-RASD use in minimally invasive right or left colectomy: Virtual Incision Corp, VI-RASD use in right or left colectomy procedures.

Right or Left colectomy: Surgical Procedures in which the VI RASD will be used.

Study summary

For patients with colon polyps (clumps of cells in the lining of the colon) treatment often requires removal of the affected portion of the colon. Both conventional laparoscopic and robotically assisted minimally invasive surgery have been shown to have reduced complication rates and shorter hospital stays.

This study aims to look at the use of the VI RASD as a robotic surgical device in right or left colectomy procedures to see if the device performs as intended and is safe for use.

Eligibility

Sex
ALL
Min age
22 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Subject is able to provide informed consent * 22-85 years of age * No history of frozen abdomen due to abdominal adhesions or multiple previous bowel obstructions * Body mass index (BMI) between 19.5- 45 kg/m2 * A weight of at least 100 lbs. (45.36 kg.). * Height of at least 60 inches (152 cm) * ASA grades I through III * Available for required postoperative follow up visits at 14 days and 30 days Exclusion Criteria: * Subject unable or unwilling to provide informed consent * Under the age of 22 or greater than the age of 85 years * Has polyps that can be completely removed with negative surgical margins by colonoscopy. * Has Stage T4 cancer diagnosis * History of abdominal adhesions or bowel obstruction * BMI of \< 19.5 and \> 45 kg/m2 * Heights \< 60 inches * ASA grades IV-VI * End stage renal disease * Liver Cirrhosis * Women who are pregnant or lactating * Active infection or has a history of local or systemic infection within 30 days of study screening * Has had major surgery within 30 days prior to study enrollment or is scheduled to have major surgery within 30 days * Has participated or is participating in another clinical study which may confound study results * In the opinion of the Investigator, patient is not likely to comply with the required protocol activities; or, has a medical condition that should exclude the patient from the study * Hemoglobin \< 8.0 * Not currently coagulopathic

Primary outcome measure(s)

  • Efficacy: Number of Participants With Successful Completion of the VI RASD Steps in Colectomy Procedures Without Conversion to Open Surgery — Intraoperative Period- Surgical Procedure Start time to Surgical Procedure End time
    Count and calculated percentage of enrolled subjects in which the VI RASD steps were successfully completed and did not require conversion to open surgery. VI RASD steps include: the VI-RASD system is inserted and deployed to corresponding abdominal cavity, used to manipulate and dissect the colon allowing for transection of the colon and small bowel, and system is removed from the abdominal cavity.
  • Determine the Safety Profile of VI-RASD as the Number of Enrolled Subjects Experiencing Either an Intraoperative and/or Postoperative Adverse Events Occurring Within 30 Days Post Procedure. — Time insertion of the VI RASD device is initiated (intraoperative) through 30 days (+/- 5 days) post procedure (post operative).
    Count and calculated percentage of enrolled subjects experiencing an intraoperative and/or postoperative adverse events.

Trial sites (3)

FacilityCityRegionStatus
Bryan Medical Center Lincoln Nebraska
Lankeanu Medical Center Wynnewood Pennsylvania
Roper Saint Francis Mount Pleasant Mt. Pleasant South Carolina

More Virtual Incision Corporation trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04703829 on ClinicalTrials.gov ↗ ← All trials in the USA